BC060267 Activators

Efcab12, characterized by its EF-hand calcium binding domain, exhibits expression in various neuroanatomical structures, including the 4th ventricle lateral recess, choroid plexus, lateral ventricle choroid plexus, and olfactory epithelium. As an ortholog to human EFCAB12, its precise function in calcium signaling pathways is vital for cellular processes within these tissues. Activation of Efcab12 involves a sophisticated interplay with multiple chemicals. Ryanodine, a receptor agonist, activates Efcab12 through increased intracellular calcium levels, impacting its EF-hand calcium binding domain. Thapsigargin, a SERCA inhibitor, indirectly activates Efcab12 by depleting ER calcium stores. Bay K8644, a calcium channel activator, influences Efcab12 through increased calcium entry. A23187, a calcium ionophore, activates Efcab12 by inducing calcium influx. Nimodipine, a calcium channel blocker, indirectly activates Efcab12 by preventing calcium entry.

Dantrolene, a receptor antagonist, inhibits Efcab12 activation by reducing intracellular calcium levels. Ionomycin, another calcium ionophore, activates Efcab12 through elevated intracellular calcium levels. Nifedipine, a calcium channel blocker, indirectly activates Efcab12 by preventing calcium entry. U73122, a PLC inhibitor, disrupts Efcab12 activation by altering intracellular calcium release. N-Phenylthiourea, a TRPA1 antagonist, blocks Efcab12 activation by reducing calcium entry. SKF 96365, a non-specific calcium channel blocker, indirectly activates Efcab12. Ruthenium Red, a calcium channel blocker, inhibits Efcab12 activation by reducing calcium entry. This intricate web of chemical regulators highlights the importance of calcium signaling pathways in modulating Efcab12. The targeted activation of Efcab12 through these chemicals offers a nuanced perspective on the intricate cellular processes and signaling cascades influenced by its EF-hand calcium binding domain.